Format

Send to

Choose Destination
Blood Cancer J. 2018 Aug 22;8(9):80. doi: 10.1038/s41408-018-0117-0.

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Author information

1
University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
2
Ospedale Pediatrico Bambino Gesù, Rome, Italy.
3
University of Pavia, Pavia, Italy.
4
Amgen Research (Munich), Munich, Germany. gerhardz@amgen.com.
5
University of Tübingen, Tübingen, Germany.
6
Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA.
7
Division for Stem Cell Transplantation and Immunology, Department of Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
8
Children's Hospital of Los Angeles, Los Angeles, CA, USA.
9
University Children's Hospital Würzburg, Würzburg, Germany.
10
Amgen Inc., Thousand Oaks, CA, USA.
11
Charité Campus Virchow, Berlin, Germany.
PMID:
30190453
PMCID:
PMC6127096
DOI:
10.1038/s41408-018-0117-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center